Mechanistic Insights into Cancer Immunotherapy and Immune-Related Adverse Events
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 April 2025 | Viewed by 2069
Special Issue Editors
Interests: cancer immunotherapy; immune-related adverse events; biomarker
Interests: immune system; cancer immunotherapy; cancer progression
Interests: tumor immune microenvironment; PD-1 immunotherapy; CD8+ T cells; T cell exhaustion; immune-related adverse events; autoimmunity; melanoma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
With the rapid evolution of cancer immunotherapy, its role in clinical treatment has become increasingly prominent. Current research in cancer immunotherapy is dedicated to recognizing and treating immune-related adverse events (irAEs) without compromising the efficacy of cancer treatment. However, the pathophysiological mechanisms underlying irAEs are not fully understood, which limits the development of targeted therapies. irAEs associated with immunotherapy remain a complex and challenging field. For this Special Issue, we are particularly interested in papers that can translate basic scientific research into clinical applications. This includes, but is not limited to, the following:
- The molecular and cellular mechanisms of irAEs in cancer immunotherapy.
- The discovery and validation of predictive biomarkers and their application in early diagnosis and personalized treatment.
- The development and evaluation of evidence-based treatment methods for specific types of irAEs.
- Multidisciplinary research approaches to address technical and methodological limitations in irAEs research.
This will be lead by Dr. Noha Abdel-Wahab, Dr. Bilal A. Siddiqui, and Dr. Kristen E. Pauken and assisted by our Topical Advisory Panel Member Dr. Avik Dutta (National Institute of Child Health and Human Development). We invite researchers, clinicians, and scientists to submit original molecular research, reviews, and case reports on the mechanisms, diagnosis, treatment, and management strategies of cancer immunotherapy and its related irAEs. We anticipate that your contributions will provide new insights into the safety and efficacy of cancer immunotherapy.
Dr. Noha Abdel-Wahab
Dr. Bilal A. Siddiqui
Dr. Kristen E. Pauken
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- immune-related adverse events
- biomarker
- immune checkpoint inhibitor
- cancer progression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
